Buthionine sulfoximine

Buthionine sulfoximine (BSO) is a sulfoximine derivative which reduces levels of glutathione and is being investigated as an adjunct with chemotherapy in the treatment of cancer.[1] The compound inhibits gamma-glutamylcysteine synthetase, the enzyme required in the first step of glutathione synthesis. Buthionine sulfoximine may also be used to increase the sensitivity of parasites to oxidative antiparasitic drugs.[2]

Buthionine sulfoximine
Names
IUPAC name
2-amino-4-(butylsulfonimidoyl)butanoic acid
Other names
BSO
Identifiers
3D model (JSmol)
ChEBI
ChemSpider
ECHA InfoCard 100.156.351
MeSH Buthionine+sulfoximine
UNII
Properties
C8H18N2O3S
Molar mass 222.305 g/mol
Density 1.29 g/mL
Melting point 215 °C (419 °F; 488 K)
Boiling point 382.3 °C (720.1 °F; 655.5 K)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

References

  1. Defty, CL; Marsden, JR (2012). "Melphalan in regional chemotherapy for locally recurrent metastatic melanoma". Current Topics in Medicinal Chemistry. 12 (1): 53–60. doi:10.2174/156802612798919187. PMID 22196271.
  2. "Definition of buthionine sulfoximine - National Cancer Institute Drug Dictionary". 2011-02-02.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.